ParcelBio develops next-generation delivery systems for RNA medicines. The company focuses on engineering novel lipid nanoparticles and delivery vehicles for therapeutic payloads. This platform aims to enhance the efficacy and targeting of nucleic acid-based therapeutics.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LVZVFounders
Product
Problem
Current RNA therapeutics often lack precise delivery mechanisms, leading to off-target effects and reduced efficacy. Traditional delivery methods struggle to target specific cell types, limiting the potential of RNA-based treatments for various diseases.
Solution
The startup is developing a programmable RNA delivery platform to enhance the precision and effectiveness of RNA therapeutics. Their technology allows for targeted delivery of messenger RNA (mRNA) to specific cell types, improving therapeutic outcomes and minimizing off-target effects. By engineering programmable delivery vehicles, the platform enables precise control over where and when RNA is expressed, offering a more durable and effective alternative to traditional pharmaceuticals. This targeted approach has the potential to revolutionize the treatment of diseases such as cancer, genetic disorders, and infectious diseases.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions focused on developing advanced RNA-based therapies.
Features
- Programmable delivery vehicles for targeted mRNA delivery
- Enhanced cell-type specificity for reduced off-target effects
- Customizable RNA expression control for precise therapeutic intervention
- Improved durability and efficacy compared to traditional RNA therapeutics